San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

Geriatric patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, highlighting the need for prospective studies to improve outcomes. Read More ›

The use of circulating tumor cells to monitor HER2 status may help to identify patients who could benefit from a modified treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch. Read More ›

ARX788-211 is a phase 2/3 randomized, multicenter, open-label trial comparing ARX788 with lapatinib and capecitabine in patients with HER2-positive, locally advanced, or metastatic breast cancer. Read More ›

To evaluate the use of tucatinib with T-DM1 for unresectable locally advanced or metastatic HER2-positive breast cancer, enrollment for the HER2CLIMB-02 trial is ongoing in the United States and planned internationally. Read More ›

Patients with HER2-positive metastatic breast cancer treated with ≥2 lines of HER2-directed therapy had better outcomes in the neratinib plus capecitabine arm compared with the lapatinib plus capecitabine arm irrespective of the baseline status of CNS metastases. Read More ›

Radius Health, Inc. (Nasdaq:RDUS) today provided an update on data from the Phase 1 005 clinical study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The data were presented at a Spotlight Presentation (Abstract 1410) during the 2017 San Antonio Breast Cancer Symposium (SABCS). Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. Read More ›

The combination of abemaciclib plus anastrozole is superior to anastrozole alone in reducing Ki67 across a spectrum of subgroups of patients with hormone receptor (HR)-positive, HER2-negative breast cancer. Read More ›

The combination of abemaciclib plus pembrolizumab is safe and effective in women with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer. Read More ›

In a retrospective cohort study of more than 17,000 patients with hormone receptor (HR)-positive, HER2-negative breast cancer, changes in the treatment paradigm have more young patients receiving ovarian suppression as part of initial therapy, and patients regardless of age receiving treatment with the CDK4/6 inhibitor palbociclib, whereas a decrease has been seen in use of tamoxifen for younger patients and overall. Read More ›

The combination of the PD-1 inhibitor pembrolizumab plus either doxorubicin or an aromatase inhibitor may be a feasible approach to treating triple-negative or hormone receptor (HR)-positive metastatic breast cancer. Read More ›

Page 9 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications